IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction

• Published in: Frontiers in immunology Vol. 9; p. 2035
• Main Authors: Orrem, Hilde L, Nilsson, Per H, Pischke, Søren E, Kleveland, Ola, Yndestad, Arne, Ekholt, Karin, Damås, Jan K, Espevik, Terje, Bendz, Bjørn, Halvorsen, Bente, Gregersen, Ida, Wiseth, Rune, Andersen, Geir Ø, Ueland, Thor, Gullestad, Lars, Aukrust, Pål, Barratt-Due, Andreas, Mollnes, Tom E
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media 12.09.2018; Frontiers Media S.A
• Subjects: C3a receptor; C5a receptors; Cardiology: 771; Clinical medical disciplines: 750; complement; IL-6; Immunologi; Immunology; inflammation; Kardiologi: 771; Klinisk medisinske fag: 750; Medical disciplines: 700; Medisinske Fag: 700; myocardial infarction; VDP; complement; C3a receptor; inflammation; C5a receptors; IL-6; myocardial infarction
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2018.02035

Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated the effect of the IL-6 receptor (IL-6R)-antagonist tocilizumab on the expression of the anaphylatoxin receptors in whole blood from non-ST-elevation myocardial infarction (NSTEMI) patients. Separately, anaphylatoxin receptor expression in peripheral blood mononuclear cells (PBMC) from patients with different entities of CAD was investigated. NSTEMI patients were randomized to one dose of tocilizumab ( = 28) or placebo ( = 32) and observed for 6 months. Whole blood samples drawn at inclusion, at day 2, 3 and after 6 months were used for mRNA isolation. Plasma was prepared for analysis of complement activation measured as sC5b-9 by ELISA. Furthermore, patients with different CAD entities comprising stable angina pectoris (SAP, = 22), non-ST-elevation acute coronary syndrome (NSTE-ACS, = 21) and ST-elevation myocardial infarction (STEMI, = 20) were included. PBMC was isolated from blood samples obtained at admission to hospital and mRNA isolated. Anaphylatoxin-receptor-expression was analyzed with qPCR using mRNA from whole blood and PBMC, respectively. Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly ( < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. (ii) Tocilizumab did not affect complement activation. (iii) In analyzes of different CAD entities, C5aR1 expression was significantly increased in all CAD subgroups compared to controls with the highest level in the STEMI patients ( < 0.001). For C5aR2 and C3aR the expression compared to controls were more moderate with increased expression of C5aR2 in the STEMI group ( < 0.05) and C3aR in the NSTE-ACS group ( < 0.05). Expression of C5aR1 and C5aR2 in whole blood was significantly attenuated by IL-6R-inhibition in NSTEMI patients. These receptors were significantly upregulated in PBMC CAD patients with particularly high levels of C5aR1 in STEMI patients.